You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

EPIPEN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Epipen, and when can generic versions of Epipen launch?

Epipen is a drug marketed by Mylan Speciality Lp and is included in one NDA. There are five patents protecting this drug.

This drug has forty-seven patent family members in eighteen countries.

The generic ingredient in EPIPEN is epinephrine. There are twenty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Epipen

A generic version of EPIPEN was approved as epinephrine by BPI LABS on July 29th, 2014.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for EPIPEN?
  • What are the global sales for EPIPEN?
  • What is Average Wholesale Price for EPIPEN?
Drug patent expirations by year for EPIPEN
Drug Prices for EPIPEN

See drug prices for EPIPEN

Recent Clinical Trials for EPIPEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jeffrey Alan Klein, MDPhase 2/Phase 3
Nasus PharmaPhase 1
Apimeds, Inc.Phase 3

See all EPIPEN clinical trials

US Patents and Regulatory Information for EPIPEN

EPIPEN is protected by five US patents.

Patents protecting EPIPEN

Automatic injector
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Automatic injector with kickback attenuation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Automatic injector with needle cover
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Automatic injector
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Automatic injector with needle cover
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Speciality Lp EPIPEN epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 019430-001 Dec 22, 1987 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Mylan Speciality Lp EPIPEN JR. epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 019430-002 Dec 22, 1987 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Mylan Speciality Lp EPIPEN epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 019430-001 Dec 22, 1987 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.